7-bromo-2,3-dimethyl-4-oxo-3,4-dihydroquinazoline | 864866-78-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-bromo-2,3-dimethyl-4-oxo-3,4-dihydroquinazoline
• 英文别名: 7-bromo-2,3-dimethyl-4(3H)-quinazolinone；7-bromo-2,3-dimethylquinazolin-4-one
• CAS: 864866-78-4
• 化学式: C₁₀H₉BrN₂O
• 分子量: 253.098
• InChiKey: ZBDUPUPSJBZOCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  7-bromo-1H-benzo[1,3]oxazine-2,4-dion 以 甲醇 为溶剂， 反应 9.0h， 生成 7-bromo-2,3-dimethyl-4-oxo-3,4-dihydroquinazoline
  参考文献：
  名称：

  EP1726585

  摘要：

  公开号：

文献信息

• [EN] BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS<br/>[FR] DÉRIVÉS DE BENZOXAZINONE POUR TRAITER DES TROUBLES INDUITS PAR GLYTL
  申请人：GLAXO GROUP LTD

  公开号：WO2011012622A1

  公开（公告）日：2011-02-03

  The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

  本发明涉及苯并噁唑酮衍生物，其制备方法，含有它们的药物组合物和药物，以及它们在治疗由GlyT1介导的疾病中的应用，包括神经系统和神经精神疾病，特别是精神病、痴呆或注意力缺陷障碍。
• [EN] INHIBITORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] INHIBITEURS D'AMIDE D'HYDROLASE D'ACIDE GRAS
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2010118155A1

  公开（公告）日：2010-10-14

  Provided herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2 R3, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating FAAH-mediated disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.

  本文提供了公式（I）的化合物或其药用可接受的盐、溶剂化合物或前药，或它们的混合物，其中Z1、Z2、X1、X2、X3、R1、R2、R3、m和n在此处被定义。还提供了包括公式I的化合物和药用可接受的赋形剂的药用可接受的组合物。还提供了治疗FAAH介导的疾病的方法，包括向需要的受试者施用本发明化合物或组合物的治疗有效量。
• Dairyl-substituted five-membered heterocycle derivative
  申请人：Hirata Yukari

  公开号：US20070173507A1

  公开（公告）日：2007-07-26

  The present invention provides the compounds represented by formula (I): (I) or pharmaceutical salts thereof, wherein: X 1 represents oxygen atoms and the like, X 2 represents nitrogen atoms and the like, X 3 represents nitrogen atoms and the like, X 4 represents nitrogen atoms and the like, R 1 represents formula (II-1): wherein X 5 represents sulfur atoms and the like, A 1 represents carbon atoms and the like, A 2 represents nitrogen atoms and the like and A ring represents phenyl group and the like, having mGluR1 inhibiting effect, and being usefull for preventing or treating convulsion, acute pain, inflammatory pain, chronic pain, brain disorder such as cerebral infarction or transient ischemick attack, psychotic disorder such as schizophrenia, anxiety, drug dependence, Parkinson's disease, or gastrointestinal disorder.

  本发明提供了由公式（I）所表示的化合物：（I）或其药物盐，其中：X1代表氧原子等，X2代表氮原子等，X3代表氮原子等，X4代表氮原子等，R1代表公式（II-1）：其中X5代表硫原子等，A1代表碳原子等，A2代表氮原子等，A环代表苯基等，具有mGluR1抑制作用，适用于预防或治疗惊厥、急性疼痛、炎症性疼痛、慢性疼痛、脑部疾病如脑梗死或短暂性脑缺血发作、精神疾病如精神分裂症、焦虑、药物依赖、帕金森病或胃肠道疾病。
• DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE
  申请人：Hirata Yukari

  公开号：US20110160208A1

  公开（公告）日：2011-06-30

  The present invention provides the compounds represented by formula (I): or pharmaceutical salts thereof, wherein: X 1 represents oxygen atoms and the like, X 2 represents nitrogen atoms and the like, X 3 represents nitrogen atoms and the like, X 4 represents nitrogen atoms and the like, R 1 represents formula (II-1): wherein X 5 represents sulfur atoms and the like, A 1 represents carbon atoms and the like, A 2 represents nitrogen atoms and the like and A ring represents phenyl group and the like, having mGluR1 inhibiting effect, and being useful for preventing or treating convulsion, acute pain, inflammatory pain, chronic pain, brain disorder such as cerebral infarction or transient ischemick attack, psychotic disorder such as schizophrenia, anxiety, drug dependence, Parkinson's disease, or gastrointestinal disorder.

  本发明提供了以下式子(I)所代表的化合物或其药物盐，其中：X1代表氧原子等，X2代表氮原子等，X3代表氮原子等，X4代表氮原子等，R1代表式子(II-1)：其中X5代表硫原子等，A1代表碳原子等，A2代表氮原子等，环A代表苯基等，具有mGluR1抑制作用，并且对于预防或治疗惊厥、急性疼痛、炎症性疼痛、慢性疼痛、脑部疾病如脑梗死或短暂性缺血性发作、精神障碍如精神分裂症、焦虑、药物依赖、帕金森病或胃肠疾病有用。
• METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF
  申请人：Heffernan Michele L. R.

  公开号：US20140179682A1

  公开（公告）日：2014-06-26

  Compounds that modulate GluR5 activity and methods of using the same are disclosed.

  本发明揭示了调节GluR5活性的化合物及其使用方法。